Olumiant (baricitinib), an anti-inflammatory medication from Eli Lilly (NYSE:LLY), is effective for reducing lung inflammation in COVID-19 patients when administered early after infection, according to a peer-reviewed study published in Cell. A NIAID-backed clinical trial known as the Adaptive COVID-19 Treatment Trial (ACTT-4) is testing baricitinib alongside the common steroid dexamethasone. The trial began in November. A related trial, ACTT-2,…